10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

Once a decade discount

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX

March 26, 2012 | About:
GuruFocus

GuruFocus

371 followers
According to GuruFocus Insider Data, these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below:

E.W. Scripps Company (SSP): SVP, CFO and Treasurer Timothy M. Wesolowski Bought 26,700 Shares

Senior Vice President, CFO and Treasurer of E.W. Scripps Company (SSP) Timothy M. Wesolowski bought 26,700 shares on 03/13/2012 at an average price of $9.4. E.W. Scripps Company is a diversified media company operating in three reportable segments: newspapers, broadcast television and category television. E.W. Scripps Company has a market cap of $534.6 million; its shares were traded at around $9.89 with and P/S ratio of 0.7.

The E.W. Scripps Company reported operating results for the fourth quarter of 2011. Consolidated revenues were $197 million, a decrease of 10.4 percent from $220 million in the fourth quarter of 2010.

Senior Vice President, CFO and Treasurer Timothy M. Wesolowski bought shares of SSP stock.

Senior Vice President and Chief Administrative Officer Lisa A. Knutson, Senior Vice President Newspapers Timothy E. Stautberg, and Director Paul K. Scripps sold shares of SSP stock.

BioMimetic Therapeutics Inc. (BMTI): CFO Lawrence E. Bullock Bought 20,000 Shares

CFO of BioMimetic Therapeutics Inc. (BMTI) Lawrence E. Bullock bought 20,000 shares on 03/20/2012 at an average price of $2.2. BioMimetic Therapeutics is a biotech company utilizing recombinant human platelet-derived growth factor (rhPDGF-BB) as its primary technology platform. BioMimetic Therapeutics Inc. has a market cap of $60.9 million; its shares were traded at around $2.3 with and P/S ratio of 35.3. BioMimetic Therapeutics Inc. had an annual average earnings growth of 1.4% over the past five years.

BioMimetic Therapeutics Inc. reported its financial results as of and for the 3 and 12 months ended Dec. 31, 2011. For the three months ended Dec. 31, 2011, the company reported a net loss of $9.9 million, or $0.35 per diluted share, compared to a net loss of $10.0 million, or $0.36 per diluted share, for the same period in 2010. For the 12 months ended Dec. 31, 2011, the company reported a net loss of $33.2 million, or $1.19 per diluted share, compared to a net loss of $33.9 million, or $1.38 per diluted share, for the same period in 2010.

CFO Lawrence E. Bullock and Director Gary E. Friedlaender bought shares of BMTI stock.

General Counsel Earl Martin Douglas sold shares of BMTI stock.

PolyOne Corp (POL): Senior Vice President and CFO Richard J. Diemer Jr. Bought 15,000 Shares

Senior Vice President and CFO of PolyOne Corp (POL) Richard J. Diemer Jr. bought 15,000 shares on 03/16/2012 at an average price of $13.67. PolyOne Corporation is an international polymer services company with operations in thermoplastic compounds, specialty resins, specialty polymer formulations, engineered films, color and additive systems, elastomer compounding and thermoplastic resin distribution. PolyOne Corp has a market cap of $1.21 billion; its shares were traded at around $13.61 with a P/E ratio of 13 and P/S ratio of 0.4. The dividend yield of PolyOne Corp stocks is 1.5%.

PolyOne Corporation reported $640.4 million of revenues for the fourth quarter of 2011, a 4% increase compared to $617.8 million in the fourth quarter of 2010. Full year revenues in 2011 increased 9% to $2.9 billion, compared to $2.6 billion in the prior year.

Chairman, President & CEO Stephen D. Newlin, Senior Vice President, CIO and CHRO Kenneth M. Smith, and Senior Vice President and President of Distribution Michael L. Rademacher sold shares of POL stock.

Senior Vice President and CFO Richard J. Diemer Jr., Executive Vice President and CFO Robert M. Patterson, and Director William Howard Powell bought shares of POL stock.

Anacor Pharmaceuticals (ANAC): Senior Vice President and CFO Geoffrey M. Parker Bought 10,000 Shares

Senior Vice President and CFO of Anacor Pharmaceuticals (ANAC) Geoffrey M. Parker bought 10,000 shares on 03/20/2012 at an average price of $6.08. Anacor Pharmaceuticals Inc. is a biopharmaceutical company engaged in discovery, development and commercialization of novel small-molecule therapeutics derived from its boron chemistry platform. Anacor Pharmaceuticals has a market cap of $182.7 million; its shares were traded at around $6.26 with and P/S ratio of 9.

Anacor Pharmaceuticals announced its financial results for the fourth quarter and year ended Dec. 31, 2011. Revenues for the quarter ended Dec. 31, 2011 were $2.6 million, compared to $3.5 million for the comparable period in 2010.

Senior Vice President and CFO Geoffrey M. Parker bought shares of ANAC stock.

Senior Vice President Program Management Kirk R. Maples sold shares of ANAC stock.

Cytori Therapeutics (CYTX): CFO Mark E. Saad Bought 10,000 Shares

CFO of Cytori Therapeutics (CYTX) Mark E. Saad bought 10,000 shares on 03/14/2012 at an average price of $2.55. Cytori Therapeutics Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. Cytori Therapeutics has a market cap of $177.1 million; its shares were traded at around $2.62 with and P/S ratio of 22.2.

Cytori Therapeutics reported its third quarter 2011 business update and financial results. Product revenues for the third quarter of 2011 increased to $2.1 million, compared to $1.5 million in the third quarter of 2010. Net cash used in operating activities improved to $7.9 million in the third quarter of 2011 from $9.0 million in the second quarter of 2011.

CEO Christopher J. Calhoun sold shares of CYTX stock.

CFO Mark E. Saad, President Marc H. Hedrick, and Director David Rickey bought shares of CYTX stock.

For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership

About the author:

GuruFocus
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 2.2/5 (6 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK